Foundation Medicine (FMI) Misses Q3 EPS by 4c, Offers FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Foundation Medicine (FMI) PT Lowered to $27 at Leerink Partners Amid Lower Forecast
November 4, 2015 7:49 AM ESTLeerink Partners analyst Dan Leonard lowered his price target on Foundation Medicine (NASDAQ: FMI) to $27.00 (from $36.00) while maintaining a Market Perform rating. The firm noted clinical volume was light and forecasts were reduced meaningfully.
Leonard commented, "FMI exceeded Street revenue expectations in the... More
